How to play the game of naming new drugs

New drug names are supposed to ring a long line of bells. They're supposed to be easy to remember, elicit some connection to the conditions they treat, a no-brainer for harried doctors to write out on a scrip and really quite clever overall from a marketing perspective. So why are we getting names like Incivek for telaprevir, or such clunkers as Yervoy, Viibryd, Zytiga, Xgeva, asks Xconomy's Luke Timmerman. "Somewhere, the folks who sell Coca-Cola must be giggling at their friends who went into pharmaceuticals," notes the veteran biotech scribe. So he talked with one of the industry's top experts are drug names to see what was up. Column

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.